The company has developed 90 national new drugs with more than four categories, including 4 national first-class drugs and 2 second-class drugs 13. The company has a number of product phalanxes, 7 of which are exclusively produced in China; 13 products were rated as national new drugs, among which letrozole raw materials and preparations and ambroxol hydrochloride raw materials and preparations were included in the national torch plan. The solid preparation, freeze-dried powder injection, sterile split needle, water injection and other dosage forms of the company's products have passed the national GMP certification, and the raw materials such as ifosfamide, etoposide and mesna have passed the US FDA verification.
In April 2000, the company applied for the first patent for new compounds, and many innovative drugs were in the preclinical research stage, which marked the strategic shift from imitation to innovation. We cherish the honor we have won and will inspire us to pursue new heights in the future development process.